
Ieva Ailte
- Postdoc; PhD
- +47 22 78 18 66
The metastatic melanoma project group aims to identify biomarkers that allow us to stratify patients into those who benefit from immunotherapy and those who do not. Immunotherapy is a highly effective treatment for a subset of patients, but there are also many who do not respond to this therapy. It is additionally associated with significant side effects and late effects, and it is costly. Identifying patients who are unlikely to benefit from immunotherapy will spare them unnecessary treatment and the burden of side effects.
The MelMet project: Biomarkers in melanoma
Read more about melanoma research and networking at OUS here (in Norwegian only):
Melanoma Meet & Greet | Melanomforeningen
Publications 2021
Inhibiting autophagy increases the efficacy of low-dose photodynamic therapy
Biochem Pharmacol, 194, 114837
DOI 10.1016/j.bcp.2021.114837, PubMed 34780750
Publications 2019
Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
Cancers (Basel), 11 (8)
DOI 10.3390/cancers11081088, PubMed 31370273
Publications 2017
Exogenous lysophospholipids with large head groups perturb clathrin-mediated endocytosis
Traffic, 18 (3), 176-191
DOI 10.1111/tra.12468, PubMed 28067430
Publications 2016
Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding
Sci Rep, 6, 30336
DOI 10.1038/srep30336, PubMed 27458147
Publications 2015
Geldanamycin Enhances Retrograde Transport of Shiga Toxin in HEp-2 Cells
PLoS One, 10 (5), e0129214
DOI 10.1371/journal.pone.0129214, PubMed 26017782